Proactive Investors - Run By Investors For Investors

CannPal Animal Therapeutics chairman buys company shares

80,000 shares at a cost of $10,193 represents a 12.7 cents per share average cost price.
dog and cat
The company is focused on medicinal cannabis treatments for dogs and cats

CannPal Animal Therapeutics Ltd (ASX:CP1) non-executive chairman Geoff Starr has purchased 80,000 shares in the company via on-market trades.

The $10,193 parcel is Starr’s first purchase of company shares and his first step to aligning himself with shareholders.

READ: CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase

CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.

In the recent December quarterly report chairman Geoff Starr said: “I’m extremely happy with the progress that CannPal has made in the December quarter, and particularly the company’s progress with our nutraceutical program, while maintaining focus on our lead pharmaceutical.

“Our strategy has been to remain focused and diligent in the development of compliant animal health products and that work is beginning to pay off as we’re getting closer towards getting CannPal in a position to explore commercialisation opportunities in 2019.

“I’m looking forward to the team continuing with the same momentum throughout the new-year.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CP1 profile View Profile

CannPal Animal Therapeutics Ltd Timeline

Related Articles

amberlight
Tue
The cannabis company's strategy is to focus solely on the massive California market, where it plans to establish a network of dispensaries with owner-operators
cannabis plan in sun
February 21 2019
The cannabis company will manufacture, infuse and package branded recreational and wellness products
cannabis leaf
May 08 2019
The company plans to leverage its portfolio of brands as well as its distribution network of more than 39,000 European pharmacies to maximize margins and profitability
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use